Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

In Q1 2024, sales of Novo's Wegovy and Ozempic totaled around $5.6 billion. This compares to $2.3 billion in sales for Lilly's Zepbound and Mounjaro.

Novo Nordisk has announced headline results from a late-stage study of its obesity candidate CagriSema in adults with type 2 diabetes (T2D). The phase 3 REDEFINE 2 trial has been evaluating ...

Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025 Provided by PR Newswire Jun 6, 2025, 1:10:00 PM.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an obesity medication that works differently than its popular Wegovy.

Still, Novo was undeterred, with a company spokesperson telling Fierce Pharma at the time that the “development of semaglutide in NASH is very much still on track and actually in phase 3.” ...

Surprisingly, the last couple of months have been a touch harder than anticipated for Novo Nordisk (NVO-2.74%).While it's still raking in cash from sales of its medications for type 2 diabetes and ...